Soleo Health announced that it joined the treatment center directory for Givlaari and can now administer it for adults with AHP.
Givlaari, managed by Alnylam Pharmaceuticals (NSDQ:ALNY), is the first FDA-approved treatment for acute hepatic porphyria (AHP) in adults. The once-monthly injection for subcutaneous use reduces the levels of neurotoxins associated with AHP attacks and other AHP disease manifestations in adults, according to a news release.
Frisco, Texas-based Soleo Health can now offer Givlaari injections for subcutaneous use in patients’ homes or at one of its ambulatory infusion centers. The company also offers its proprietary clinical outcomes program, SoleMetrics, to collect and produce real-world data over time to gather outcomes throughout the patient’s journey with Givlaari.
“We are once again expanding our portfolio of infusible and injectable specialty pharmaceuticals to elevate our levels of quality patient care and therapeutic service offerings. Our role in the administration of Givlaari complements the many other rare or ultra-rare drug distribution products and personalized care we provide,” Soleo Health CEO Drew Walk said in the release. “Soleo Health has established an expertise in leveraging SoleMetrics for these specialty pharmaceuticals and will do the same for those adults with AHP through the collection and analysis of critical outcomes data.
“Broadening our therapeutic portfolio continues to differentiate Soleo Health in the serving of patients with rare and ultra-rare diseases.”
